Plavix, Iscover(clopidogrel)
Clopidogrel, DuoCover, DuoPlavin, Grepid, Iscover, Plavix, Zopya, Zylagren, Zyllt (clopidogrel) is a small molecule pharmaceutical. Clopidogrel was first approved as Plavix on 1997-11-17. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, myocardial infarction, peripheral vascular diseases, and stroke. It is known to target P2Y purinoceptor 12.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Clopidogrel, Plavix (discontinued: Clopidogrel)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 10% methyl salicylate pain relief patch | C200263 | 2024-06-27 |
| 1st medxpatch | unapproved drug other | 2026-08-11 |
| 365 whole foods market anticavity/antigingivitis mouthwash | OTC monograph not final | 2022-05-12 |
| 5kind dmso | C200263 | 2025-12-02 |
| 5kind dmso for muscles and joints relief | C200263 | 2026-10-19 |
| 5kind dmso roll-on pain relieving | C200263 | 2026-10-28 |
| 701 dieda zhengtong yaogao medicated | OTC monograph not final | 2019-11-13 |
| 701 dieda zhengtong yaogao medicated plaster | OTC monograph not final | 2014-06-26 |
| abejas y viboras roll on | C200263 | 2025-07-22 |
| absolut skin spf 50 moisturizing sunscreen | C200263 | 2025-12-22 |
Show 722 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
3201 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | 11 | 29 | 38 | 147 | 105 | 323 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 12 | 20 | 35 | 71 | 58 | 192 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 6 | 12 | 26 | 62 | 40 | 139 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 7 | 16 | 41 | 29 | 52 | 137 |
| Healthy volunteers/patients | — | — | — | 102 | 6 | — | 7 | 19 | 133 |
| Ischemic stroke | D000083242 | — | — | 4 | 14 | 45 | 27 | 41 | 124 |
| Coronary disease | D003327 | — | — | 1 | 12 | 8 | 53 | 46 | 116 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | 13 | 9 | 50 | 44 | 113 |
| Infarction | D007238 | EFO_0009463 | — | 4 | 8 | 15 | 43 | 34 | 99 |
| Anesthesia | D000758 | — | — | 7 | 4 | 10 | 29 | 33 | 81 |
Show 388 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 7 | 13 | 1 | — | 3 | 24 |
| Lymphoma | D008223 | — | C85.9 | 9 | 8 | 1 | — | — | 14 |
| Glioblastoma | D005909 | EFO_0000515 | — | 11 | 3 | 1 | — | 1 | 13 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 10 | 4 | 1 | — | — | 12 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 3 | 2 | 5 | — | 2 | 11 |
| Leukemia | D007938 | — | C95 | 6 | 6 | 1 | — | 1 | 10 |
| Asthma | D001249 | EFO_0000270 | J45 | 4 | 4 | 1 | — | 2 | 10 |
| Basal cell neoplasms | D018295 | — | — | 1 | 3 | 5 | — | 3 | 10 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 4 | 1 | — | 4 | 9 |
| Dyslipidemias | D050171 | — | — | — | 4 | 3 | — | 2 | 9 |
Show 139 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 3 | 5 | — | — | 2 | 10 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 2 | 9 | — | — | — | 10 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | 3 | 6 | — | — | — | 9 |
| Myelodysplastic syndromes | D009190 | — | D46 | 6 | 5 | — | — | — | 8 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 4 | — | — | — | 8 |
| Obstructive lung diseases | D008173 | — | — | 3 | 4 | — | — | 1 | 8 |
| Multiple myeloma | D009101 | — | C90.0 | 6 | 2 | — | — | — | 8 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 2 | — | — | 3 | 8 |
| Dermatitis | D003872 | — | L30.9 | 2 | 7 | — | — | — | 8 |
| Glioma | D005910 | EFO_0000520 | — | 4 | 3 | — | — | 1 | 7 |
Show 211 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep wake disorders | D012893 | — | G47 | 2 | — | — | — | 4 | 6 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 5 | 6 |
| Asymptomatic diseases | D058070 | — | — | 1 | — | — | — | 5 | 6 |
| Hemostasis | D006487 | — | — | 2 | — | — | — | 3 | 5 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | 4 | 5 |
| Therapeutic equivalency | D013810 | — | — | 4 | — | — | — | — | 4 |
| Heart disease risk factors | D000082742 | — | — | 3 | — | — | — | 1 | 4 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | 3 | 4 |
| Addictive behavior | D016739 | EFO_0004347 | — | 3 | — | — | — | 1 | 4 |
| Pharmacokinetics | D010599 | — | — | 4 | — | — | — | — | 4 |
Show 68 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | — | — | 8 | 8 |
| Surgical blood loss | D016063 | — | — | — | — | — | — | 6 | 6 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 6 | 6 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | — | — | — | 5 | 5 |
| Dental plaque | D003773 | — | — | — | — | — | — | 5 | 5 |
| Drug resistance | D004351 | — | Z16.30 | — | — | — | — | 4 | 4 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 3 | 3 |
| Deglutition disorders | D003680 | — | R13.1 | — | — | — | — | 3 | 3 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 3 | 3 |
| Hemostatic disorders | D020141 | — | — | — | — | — | — | 3 | 3 |
Show 286 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clopidogrel |
| INN | clopidogrel |
| Description | Clopidogrel is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks. It has a role as a platelet aggregation inhibitor, an anticoagulant and a P2Y12 receptor antagonist. It is a thienopyridine, a member of monochlorobenzenes and a methyl ester. It is functionally related to a ticlopidine. |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1 |
Identifiers
| PDB | — |
| CAS-ID | 113665-84-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1771 |
| ChEBI ID | 37941 |
| PubChem CID | 60606 |
| DrugBank | DB00758 |
| UNII ID | A74586SNO7 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Methylphenidate – RVL Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Medrol – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Plavix – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Plavix – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Concerta – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Bloxiverz – Avadel Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Daytrana – Shire
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Clopidogrel
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 820,299 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clopidogrel, Clopidogrel 75mg, Clopidogrel bisulfate, Clopidogrel kit, Clopidrogrel, Concerta, Cotempla xr-odt, Covaryx, Covaryx covaryx, Daytrana, Diclovix m, Dyural 40 kit, Dyural 80 kit, Dyural 80-lm, Dyural lm kit, Eemt, Eemt eemt, Esterified estrogens and methyltestosterone, Esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength, Estratest f.s., Estratest f.s. estratest h.s., Estratest fs estratest hs, Fenovar, Healthy mamabe well rounded, Hydrocodone bitartrate and homatropine methylbromide, Jornay pm, Metadate cd, Metadate er, Methylene blue, Methylin, Methylphenidate, Methylphenidate extended-release, Methylphenidate hydrochloride, Methylphenidate hydrochloride (la), Methylphenidate hydrochloride cd, Methylphenidate hydrochloride extended release, Methylphenidate transdermal system, Orthaphen, Orthrexo, Perseris, Physicians ez use m-pred, Plavix, Provayblue, Quillichew er, Quillivant, Relexxii, Ritalin, Torvex, Torvexa, Varophen
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
325,752 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use